| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 |
Revenue  | 952 | 778 | 800 | 811 | 1,223 | 1,029 | 989 | 1,086 | 974 | 986 | 1,025 | 1,098 | 1,242 | 1,193 | 1,564 | 1,585 | 1,557 | 1,483 | 1,673 | 1,784 | 1,621 | 1,712 | 1,765 | 1,885 | 2,060 | 1,808 | 1,945 | 2,223 | 2,476 | 2,217 | 2,384 | 3,020 | 3,929 | 3,516 | 3,551 | 4,135 | 3,912 | 4,543 | 3,604 | 3,826 | 4,415 | 3,990 | 4,356 | 4,240 |
| Expenses | 653 | 606 | 727 | 615 | 740 | 719 | 706 | 762 | 738 | 735 | 786 | 836 | 937 | 886 | 982 | 1,160 | 1,137 | 1,029 | 1,174 | 1,307 | 1,247 | 1,284 | 1,363 | 1,459 | 1,476 | 1,427 | 1,515 | 1,733 | 1,911 | 1,783 | 1,894 | 2,624 | 2,820 | 2,741 | 2,769 | 3,051 | 3,013 | 2,813 | 2,905 | 3,070 | 3,339 | 3,193 | 3,472 | 3,633 |
| EBITDA | 300 | 172 | 73 | 196 | 483 | 309 | 283 | 324 | 236 | 250 | 239 | 262 | 306 | 307 | 582 | 425 | 420 | 454 | 499 | 477 | 373 | 428 | 402 | 427 | 584 | 380 | 430 | 489 | 565 | 434 | 490 | 396 | 1,109 | 775 | 782 | 1,084 | 900 | 1,730 | 699 | 756 | 1,077 | 797 | 884 | 607 |
| Operating Profit % | 21 % | 20 % | 6 % | 22 % | 21 % | 27 % | 25 % | 27 % | 20 % | 21 % | 19 % | 21 % | 20 % | 21 % | 26 % | 25 % | 26 % | 29 % | 25 % | 25 % | 20 % | 24 % | 22 % | 21 % | 20 % | 19 % | 18 % | 20 % | 21 % | 17 % | 18 % | 11 % | 25 % | 20 % | 18 % | 14 % | 22 % | 17 % | 18 % | 19 % | 23 % | 18 % | 19 % | 12 % |
| Depreciation | 59 | 59 | 61 | 64 | 65 | 66 | 68 | 70 | 73 | 99 | 94 | 97 | 95 | 99 | 112 | 117 | 120 | 124 | 132 | 144 | 152 | 167 | 178 | 186 | 184 | 195 | 202 | 206 | 212 | 218 | 231 | 301 | 364 | 358 | 389 | 415 | 407 | 405 | 420 | 425 | 436 | 455 | 473 | 515 |
| Interest | 0 | 4 | 3 | 2 | 21 | 6 | 7 | 9 | 5 | 16 | 14 | 15 | 17 | 18 | 19 | 19 | 16 | 17 | 14 | 18 | 17 | 13 | 7 | 5 | 34 | 20 | 23 | 15 | 11 | 20 | 30 | 120 | 249 | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 | 210 |
| Profit Before Tax | 249 | 165 | 20 | 141 | 409 | 238 | 208 | 245 | 159 | 135 | 132 | 150 | 193 | 190 | 451 | 289 | 284 | 313 | 354 | 315 | 204 | 249 | 218 | 236 | 366 | 166 | 206 | 269 | 343 | 197 | 229 | -26 | 497 | 184 | 214 | 808 | 319 | 1,146 | 98 | 156 | 487 | 97 | 171 | -68 |
| Tax | 32 | 34 | 18 | 19 | 55 | 55 | 42 | 54 | 10 | 38 | 43 | 36 | 41 | 52 | 73 | 46 | 41 | 85 | 100 | 85 | 45 | 81 | 22 | 49 | 69 | 57 | 46 | 49 | 59 | 30 | 147 | -5 | 82 | 35 | 42 | 55 | 96 | 284 | 71 | 75 | 27 | 8 | 39 | -16 |
| Net Profit | 217 | 131 | 2 | 122 | 354 | 182 | 167 | 191 | 148 | 98 | 89 | 114 | 153 | 138 | 378 | 243 | 243 | 228 | 254 | 230 | 159 | 168 | 195 | 187 | 296 | 108 | 160 | 220 | 284 | 167 | 82 | -21 | 415 | 149 | 173 | 753 | 223 | 862 | 27 | 81 | 459 | 89 | 133 | -52 |
| EPS in ₹ | 10.08 | 6.31 | -0.54 | 5.30 | 16.97 | 8.49 | 7.48 | 8.72 | 6.49 | 1.38 | 1.17 | 1.56 | 2.21 | 1.02 | 3.00 | 3.67 | 3.61 | 1.74 | 1.82 | 1.71 | 1.04 | 1.26 | 1.39 | 1.42 | 2.13 | 0.71 | 1.16 | 1.57 | 2.00 | 1.21 | 0.39 | -0.35 | 2.62 | 0.85 | 1.05 | 5.52 | 1.13 | 5.51 | -0.13 | 0.21 | 2.88 | 0.26 | 0.66 | 1.08 |
Biocon
Biocon
346.55
-3.25
(-0.93%)
Market Cap
56,172.56 Cr
PE Ratio
90.21
Volume
6,56,340.00
Day High - Low
351.95 - 346.00
52W High-Low
424.95 - 305.00
There are new updates from the company1 day ago
View
Key Fundamentals
Market Cap
56,172.56 Cr
EPS
8.46
PE Ratio
90.21
PB Ratio
1.50
Book Value
233.84
EBITDA
4,374.50
Dividend Yield
0.11 %
Industry
Healthcare Sector
Pharmaceuticals Return on Equity
5.16
Debt to Equity
0.84
Analyst Rating and Forecast
- By Refinitiv from16 analysts
Actual
Company News
View All News
Biocon Limited has scheduled investor meetings at HSBC Global Investment Summit 2026 in Hong Kong on April 14-15, 2026, followed by an investor roadshow in Singapore on April 16-17, 2026.
Biocon Limited submitted its quarterly certificate under SEBI Regulation 74(5) for Q4 FY26, confirming compliance with dematerialization and rematerialization requirements for the quarter ended March 31, 2026.
Biocon Limited announces commercial launch of Bosayaâ„¢ and Aukelsoâ„¢ denosumab biosimilars in the United States following FDA approval with interchangeable designation in September 2025.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,717.90 | #1 4,12,181.75 | 37.54 | #1 54,729.00 | 9.71 | #1 10,980 | 16.07 | 42.98 | |
5,901.50 | 1,56,666.28 | 62.98 | 9,712.00 | 18.67 | 2,191 | -1.02 | 37.15 | |
4,057.00 | 1,37,307.32 | 60.00 | 11,539.40 | 6.99 | 1,911 | 26.24 | 37.30 | |
2,278.80 | 1,04,151.01 | 22.46 | 22,909.50 | 13.74 | 3,306 | #1 37.44 | 50.67 | |
1,204.20 | 1,00,507.71 | 18.01 | 33,741.20 | 16.73 | 5,725 | -15.28 | 35.49 | |
1,229.20 | 99,292.40 | 21.66 | 28,409.50 | 7.12 | 5,291 | -57.18 | 35.83 | |
900.15 | 90,576.15 | #1 17.85 | 23,511.00 | 18.55 | 4,615 | -0.32 | 50.58 | |
2,034.70 | 83,993.45 | 46.75 | 12,744.20 | #1 20.90 | 2,007 | 7.65 | 46.83 | |
1,329.40 | 77,211.77 | 22.25 | 32,345.60 | 9.43 | 3,484 | 7.59 | 63.41 | |
5,257.00 | 62,855.32 | 25.90 | 13,458.30 | 3.70 | 2,216 | 1.90 | 43.47 |
Growth Rate
Revenue Growth
5.43 %
Net Income Growth
10.14 %
Cash Flow Change
37.49 %
ROE
0.58 %
ROCE
1.95 %
EBITDA Margin (Avg.)
-0.38 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Fixed Assets | 1,630 | 1,749 | 3,626 | 3,700 | 4,471 | 5,971 | 6,364 | 6,569 | 29,468 | 30,644 | 31,963 |
| Current Assets | 2,563 | 3,971 | 4,048 | 4,149 | 4,823 | 5,325 | 7,600 | 8,382 | 12,334 | 15,179 | 16,286 |
| Capital Work in Progress | 1,677 | 2,240 | 839 | 1,303 | 1,899 | 2,196 | 2,800 | 4,110 | 7,317 | 7,993 | 8,508 |
| Investments | 230 | 901 | 1,253 | 675 | 1,012 | 966 | 1,952 | 1,588 | 2,069 | 1,000 | 1,127 |
| Other Assets | 2,839 | 3,569 | 3,676 | 4,312 | 4,811 | 5,311 | 7,406 | 8,127 | 13,189 | 16,434 | 17,199 |
| Total Equity & Liabilities | 6,375 | 8,458 | 9,394 | 9,990 | 12,192 | 14,444 | 18,522 | 20,394 | 52,043 | 56,071 | 58,797 |
| Current Liabilities | 1,555 | 1,666 | 1,678 | 2,141 | 3,038 | 4,008 | 4,210 | 3,828 | 8,511 | 15,359 | 14,334 |
| Non Current Liabilities | 1,378 | 2,493 | 2,502 | 2,200 | 2,448 | 3,053 | 5,805 | 7,096 | 21,043 | 15,437 | 16,751 |
| Total Equity | 3,443 | 4,300 | 5,214 | 5,649 | 6,707 | 7,383 | 8,508 | 9,470 | 22,489 | 25,275 | 27,713 |
| Reserve & Surplus | 3,171 | 3,992 | 4,738 | 4,881 | 5,798 | 6,106 | 7,027 | 7,832 | 17,267 | 19,183 | 21,044 |
| Share Capital | 100 | 100 | 100 | 300 | 300 | 600 | 600 | 600 | 600 | 600 | 600 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -94 | 300 | -47 | -261 | 210 | 165 | 72 | -243 | 641 | -380 | 2,004 |
| Investing Activities | -491 | -1,138 | -510 | -684 | -703 | -1,505 | -3,651 | -1,662 | -14,260 | -1,002 | -203 |
| Operating Activities | 211 | 371 | 640 | 662 | 1,155 | 1,283 | 1,160 | 1,177 | 1,853 | 2,954 | 4,061 |
| Financing Activities | 186 | 1,068 | -178 | -240 | -242 | 388 | 2,564 | 242 | 13,049 | -2,333 | -1,854 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Jan 2026 |
| Promoter | 60.67 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 60.64 % | 54.45 % | 54.45 % | 54.45 % | 44.91 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 7.96 % | 6.55 % | 5.63 % | 5.90 % | 5.93 % | 5.66 % | 5.66 % | 6.04 % | 6.61 % | 7.39 % | 7.14 % |
| DIIs | 6.65 % | 6.89 % | 6.87 % | 6.83 % | 7.79 % | 7.30 % | 7.76 % | 8.63 % | 11.90 % | 12.56 % | 14.08 % | 14.51 % | 13.68 % | 14.30 % | 14.44 % | 15.37 % | 15.72 % | 22.82 % | 22.10 % | 21.71 % | 24.16 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.89 % | 11.03 % | 11.49 % | 11.37 % | 10.87 % | 10.72 % | 12.07 % | 12.46 % | 13.21 % | 13.34 % | 13.61 % | 14.47 % | 15.53 % | 14.63 % | 14.57 % | 14.07 % | 13.63 % | 12.58 % | 12.71 % | 12.38 % | 10.23 % |
| Others | 21.79 % | 21.44 % | 21.00 % | 21.16 % | 20.70 % | 21.35 % | 19.54 % | 18.27 % | 14.26 % | 13.46 % | 3.70 % | 3.83 % | 4.52 % | 4.53 % | 4.42 % | 4.27 % | 4.34 % | 4.10 % | 4.12 % | 4.06 % | 13.55 % |
| No of Share Holders | 0 | 3,11,349 | 3,38,815 | 3,63,447 | 3,64,502 | 3,47,911 | 3,41,016 | 3,69,816 | 4,11,086 | 4,12,441 | 4,15,046 | 4,34,339 | 4,70,261 | 4,43,513 | 4,39,503 | 4,27,705 | 4,24,297 | 4,30,217 | 4,13,191 | 3,94,279 | 3,94,215 |
Dividend History
| Annual Cash Flows | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 3 | 1 | 1 | 0.00 | 0.00 | 0.5 | 1.5 | 0.5 | 0.5 | 0.00 |
| Dividend Yield (%) | 1.01 | 0.33 | 0.37 | 0.00 | 0.00 | 0.25 | 0.57 | 0.15 | 0.14 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 13 Jun 2019 |  Bonus | 1:1 | 12 Jun 2019 | 271.45 | 257.90 |
| 01 Jul 2022 |  Dividend | ₹ 0.50 /share | 30 Jun 2022 | 382.30 | 308.40 |
| 07 Jul 2023 | Dividend | ₹ 1.50 /share | 07 Jul 2023 | 240.45 | 259.50 |
| 05 Jul 2024 | Dividend | ₹ 0.50 /share | 05 Jul 2024 | 311.90 | 361.10 |
| 09 Aug 2024 |  Annual General Meeting | NA | 09 Aug 2024 | 311.90 | 339.20 |
| 30 Oct 2024 |  Quarterly Result Announcement | NA | 30 Oct 2024 | 370.65 | 326.85 |
| 30 Jan 2025 | Quarterly Result Announcement | NA | 30 Jan 2025 | 372.95 | 355.70 |
| 08 May 2025 | Quarterly Result Announcement | NA | 08 May 2025 | 339.10 | 346.50 |
| 04 Jul 2025 | Dividend | ₹ 0.50 /share | 04 Jul 2025 | 346.50 | 374.40 |
| 07 Aug 2025 | Quarterly Result Announcement | NA | 07 Aug 2025 | 372.05 | 360.60 |
| 08 Aug 2025 | Annual General Meeting | NA | 08 Aug 2025 | 346.50 | 364.20 |
| 11 Nov 2025 | Quarterly Result Announcement | NA | 11 Nov 2025 | 352.25 | 382.15 |
| 31 Dec 2026 |  Extraordinary General Meeting | NA | 31 Dec 2026 | 392.80 | 390.40 |
| 12 Feb 2026 | Quarterly Result Announcement | NA | 12 Feb 2026 | 371.80 | 375.80 |
Announcements
Company Statement
1 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation1 day ago
1 day agoCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 20181 day ago
1 day agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release1 day ago
1 day agoIntimation Of Change In Name Of Step-Down Subsidiary Of The Company9 days ago
9 days agoAmendment To Trust DeedMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Change in ManagementMar 27, 2026
Mar 27, 2026Announcement under Regulation 30 (LODR)-Change in DirectorateMar 27, 2026
Mar 27, 2026Board Meeting Outcome for Outcome Of Board MeetingMar 27, 2026
Mar 27, 2026Closure of Trading WindowMar 26, 2026
Mar 26, 2026Notification To Stock ExchangesMar 12, 2026
Mar 12, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 05, 2026
Mar 05, 2026Announcement under Regulation 30 (LODR)-AcquisitionMar 03, 2026
Mar 03, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMar 02, 2026
Mar 02, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 25, 2026
Feb 25, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 24, 2026
Feb 24, 2026Announcement under Regulation 30 (LODR)-Earnings Call TranscriptFeb 17, 2026
Feb 17, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 17, 2026
Feb 17, 2026Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2026
Feb 14, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Investor PresentationFeb 13, 2026
Feb 13, 2026Announcement under Regulation 30 (LODR)-Monitoring Agency ReportFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 12, 2026
Feb 12, 2026Outcome Of Board Meeting - In-Principle Approval Of AcquisitionFeb 12, 2026
Feb 12, 2026Outcome Of Board MeetingFeb 12, 2026
Feb 12, 2026Board Meeting Outcome for Outcome Of Board Meeting- Quarterly ResultsFeb 12, 2026
Feb 12, 2026Outcome Of Board Meeting-Financial ResultsFeb 12, 2026
Feb 12, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseFeb 07, 2026
Feb 07, 2026Buyback Of Commercial PapersJan 30, 2026
Jan 30, 2026Intimation Of Record Date For Buy Back Of Listed Commercial Paper Issued By The CompanyJan 28, 2026
Jan 28, 2026Intimation Of Record Date For Buy Back Of Listed Commercial Paper Issued By The CompanyJan 28, 2026
Jan 28, 2026Notification To Stock ExchangesJan 28, 2026
Jan 28, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 28, 2026
Jan 28, 2026Certificate Pursuant To SEBI Master Circular No. SEBI/HO/DDHS/Ddhspod/
P/CIR/2025/0000000137 Dated October 15 2025Jan 21, 2026
Jan 21, 2026Announcement under Regulation 30 (LODR)-Updates on AcquisitionJan 21, 2026
Jan 21, 2026Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 20, 2026
Jan 20, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 15, 2026
Jan 15, 2026Announcement under Regulation 30 (LODR)-AllotmentJan 14, 2026
Jan 14, 2026Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJan 14, 2026
Jan 14, 2026Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJan 14, 2026
Jan 14, 2026Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJan 14, 2026
Jan 14, 2026Board Meeting Intimation for Intimation For The Board Meeting And Earnings Conference Call For Analysts And InvestorsJan 13, 2026
Jan 13, 2026Announcement under Regulation 30 (LODR)-Qualified Institutional PlacementJan 12, 2026
Jan 12, 2026Intimation Of Approval Of Unaudited Condensed Consolidated Interim Financial StatementsJan 12, 2026
Jan 12, 2026Notification To Stock ExchangesJan 12, 2026
Jan 12, 2026Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2026
Jan 08, 2026Intimation Of Record Date For Commercial PaperJan 08, 2026
Jan 08, 2026Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJan 06, 2026
Jan 06, 2026Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011Jan 06, 2026
Jan 06, 2026Mutual Fund Holdings
Technical Indicators
RSI(14)
Neutral 39.06
ATR(14)
Less Volatile 12.96
STOCH(9,6)
Neutral 21.71
STOCH RSI(14)
Oversold 17.48
MACD(12,26)
Bearish -3.39
ADX(14)
Strong Trend 28.51
UO(9)
Bearish 40.14
ROC(12)
Downtrend But Slowing Down -8.57
WillR(14)
Neutral -74.95
About Biocon
Biocon Limited is India's largest fully-integrated biopharmaceutical company, focusing on biotechnology products and research services. Founded in 1978, Biocon specializes in treating diabetes, cancer, and autoimmune diseases. The company develops and commercializes novel biologics, biosimilars, complex small molecule APIs, and generic formulations for global markets. Biocon's product portfolio includes cardiology,...more
Listing Date
07 Apr, 2004(22 Years,
2 days)
Website
Chairperson NameKiran Mazumdar Shaw
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
